BMO Global Asset Management: Using Low Volatility ETFs to Stay Invested Through Market Swings
BMO’s Zayla Saunders explains how low volatility ETFs are playing a key role in portfolio risk management and investor confidence.
How beta-driven strategies are helping investors balance risk and long-term growth
In today’s uncertain markets, keeping investors calm and committed to their long-term goals is more important than ever. That’s where low volatility strategies come in—designed to reduce exposure to highly volatile stocks and help portfolios weather market downturns. Zayla Saunders, from BMO Global Asset Management, explains how BMO uses five-year beta as a core metric to identify stocks less sensitive to broad market swings.
At BMO, the approach goes beyond screening. With thoughtful portfolio construction and sector constraints, the goal is to maintain diversification and control risk. Saunders emphasizes that understanding the methodology behind a low volatility product is essential. Is it based on beta or standard deviation? What time frame is used? These details can shape outcomes dramatically.
Today, more investors are using low volatility ETFs as stabilizers—either as core holdings or defensive positions alongside growth assets. By managing both sector concentration and currency exposure, BMO aims to provide solutions that support smoother returns, even in global markets. These ETFs are designed to help investors stay invested and maintain a stable risk profile through volatile conditions—without needing to time the market.
Watch their video HERE
Published by BTV - The Agency
Discover Investment Opportunities with BTV. Delivering engaging content to Investors for 25+ years.
.jpg)
You might also like
.jpeg)
Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.
